Table 8.2Pharmaceutical options for treating HMB; discuss the risks and benefits of each option with the woman and provide information and support to aid decision making

Pharmaceutical treatmentHow it worksWhat is it?Effect on menstrual bleedingIs it a contraceptive?Will it impact on future fertility?Possible unwanted outcomes
Levonorgestrel-releasing intrauterine system (LNG-IUS)Prevents proliferation of the endometriumA small plastic device, placed in the uterus, which slowly releases progestogenBleeding reduced by up to 95%; full benefit may not be seen for 6 monthsYesNoCommon: irregular bleeding that may last for over 6 months; hormone-related problems such as breast tenderness, acne or headaches, which, if present, are generally minor and transient

Less common amenorrhoea

Rare: uterine perforation at the time of IUS insertion
Tranexamic acidIt is an antifibrinolyticTwo tablets orally, 3 to 4 times a day, from day 1 of the cycle for up to 4 daysBleeding reduced by up to 58%NoNoLess common: indigestion; diarrhoea; headaches
Nonsteroidal anti-inflammatory drugs (NSAIDs)Reduces production of prostaglandinTablets orally from day 1, or just before, until heavy blood loss has stoppedBleeding reduced by up to 49%NoNoCommon: indigestion; diarrhoea

Rare: worsening of asthma in sensitive individuals; peptic ulcers with possible bleeding and peritonitis
Combined oral contraceptives (COCsPrevents proliferation of the endometriumOne pill daily for 21 days, followed by a 7 day breakBleeding reduced by 43%YesNoCommon: mood changes; headaches; nausea; fluid retention; breast tenderness

Rare: deep vein thrombosis; stroke; heart attacks
Oral progestogen (norethisterone)Prevents proliferation of the endometriumTablets, orally, 15 mg from day 5 to day 26 of cycleBleeding reduced by up to 83% in the long termYesNoCommon: weight gain; bloating; breast tenderness; headaches; acne (but all are usually minor and transient)

Rare: depression
Injected or implanted progestogenPrevents proliferation of the endometriumInjected intramuscularly every 12 weeks; a subdermal implant is also available that is licensed for 3 yearsBleeding is likely to stop completelyYesNoCommon: weight gain; irregular bleeding; amenorrhoea; premenstrual-like syndrome (including bloating, fluid retention, breast tenderness)

Less common: small loss of bone mineral density, largely recovered when treatment is discontinued
Gonadotrophin-releasing hormone analogue (GnRH-a)Stops production of estrogen and progesteroneMonthly injection (for 3–6 months); if used for more than 6 months, ‘add-back’ therapy is recommendedBleeding stopped completely in 89% of womenNoNoCommon: menopausal-like symptoms (such as hot flushes, increased sweating, vaginal dryness)

Less common: osteoporosis, particularly trabecular bone with longer than 6 months' use

From: 8, Pharmaceutical treatments for HMB

Cover of Heavy Menstrual Bleeding
Heavy Menstrual Bleeding.
NICE Clinical Guidelines, No. 44.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2007 Jan.
Copyright © 2007, National Collaborating Centre for Women's and Children's Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.